Ann: ResApp to Present at Upcoming Conferences in March, page-14

I disagree on the point he made that it points to disappointing results. Pure speculation with no evidence to back any of it up. I do agree that BL should not say they are not important but what I think BL was trying to emphasis that the USTrial results take priority to fast track this to FDA. Makes sense to me they are prioritising US results. Do you want them to take time away from analysing US results to slow down the FDA process? I certainly do not.